Camber Pharmaceuticals said it recalled some of its pneumonia medicine after it discovered the drug may be contaminated with the Bacillus cereus bacteria, according to a U.S. Food and Drug Administration (FDA) announcement.
The voluntary recall impacts one lot of Atovaquone Oral Suspension, USP in either 750-milligram or 5-milliliter doses to the consumer level due to possible contamination, the March 31 announcement said. The drug is meant to prevent and treat pneumonia caused by Pneumocystis jiroveci, a type of fungus that can cause infections in adults and teens who can’t tolerate other drugs.
